FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “Lexaria Bioscience Corp. Skyrocketed 26% Following Positive Study Results”
Lexaria Bioscience Corp. (NASDAQ: LEXX) surged over 26% in premarket trading after the company announced that its tolerability and pharmacokinetic study VIRAL-A20-3 has been completed with positive results.
The study demonstrated that DehydraTECHTM enabled colchicine, the latest of several drugs Lexaria has successfully tested with known SARS-CoV-2 antiviral properties, benefited from the proprietary formulation and processing, resulting in increased delivery.
Lexaria Bioscience Corp.’s proprietary drug delivery technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules, thereby lowering overall dosing.
For more information, please visit: Lexaria Bioscience Corp.
About The Buzz: A Financial Buzz Show on daily news, covering the most up to date financial information. The Buzz intends to provide factual and relevant information for its audience. The Buzz is 100% original content, created by Financial Buzz Media. Located on Wall Street in the heart of New York City’s financial district, FinancialBuzz.com is a credible source for the world’s latest trending financial and economic news. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content.